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ABSTRACT 
Background: Peripherally inserted central catheters (PICCs) are commonly being used in haematological diseases for 
treatment and now are being used even in haemopoietic stem cells transplantation. The present study was planned with an 
objective to study the complications, safety and efficacy of PICCs in haemopoietic stem cell transplantation for 
haematological diseases. Methods: A prospective cohort study was conducted in stem cell transplantation department of our 
tertiary care cancer hospital for a period of two and half years as per the proforma. All patients with hematological cancer who 
were undergoing stem cell transplantation were enrolled and were followed up until catheter removal or patient death. The 
basic information was recorded at the time of PICC insertion, weekly care, and removal after the transplantation. The data 
were analyzed to study the aims and objectives of the study. Results: Seventy two PICCs were inserted over a period of two 
and half years for a total of 8048 catheter-days (mean of 111.77 +/_ 66.55 days i.e 3.7 months, range: 9 to 269 days). Out of 
these 72 PICCs, 11 (15.27%) PICCs had complications and all of them were removed at the rate of 1.35/1000 PICC-days. 
Catheter related blood stream infection (CRBSI) was higher in allogenic transplant group (16%) than in autologous group 
(2.5%) while thrombosis was present in allogenic group only. Mortality due to non-PICC complications was higher in 
allogenic transplant (40%) than in the autologous group (7.5%). Conclusion: PICCs plays an integral part to supportive care in 
hematopoietic stem cell transplantation for hematological cancers. 
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igh-dose chemotherapy followed by 
hematopoietic stem cell transplantation (HSCT) is 
one of the standard of care for many 
hematological malignancies [1,2,3].
 
HSCT is of two types, 
autologous stem cell transplantation especially for cancers 
like multiple myeloma, lymphoma and allogenic stem cell 
transplantation for leukemias. The management of patients 
undergoing to stem cell transplantation requires a central 
line for administration of high-dose chemotherapy as well 
as stem cell infusion. Hence, the use of peripherally 
inserted central catheters (PICCs) for this intermediate-
term access has been increased significantly from the last 
few years [4]. PICCs were first described in 1975 [5]  as a 
substitute for central venous catheters such as subclavian 
catheters that have higher rates of infection. PICCs provide 
guarded intravenous access to a variety of indications [6] 
which include any infusate, regardless of pH, osmolarity or 
other chemical properties of the medication. Intravenous 
medications especially high doses chemotherapies are 
toxic to the peripheral venous endothelium and hence 
requires central venous admission to avoid this damage 
[7]. The materials used to make PICCs are either silicon 
rubber or polyurethane material, silicon being associated 
with less thrombosis [8]. The recent advances in 
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hematological malignancies have enabled us to cure many 
cases while the rest get varying degrees of relief. But, 
relief from symptoms including both physical and 
emotional is to be provided to all. Hence, ”Supportive 
Oncology” is developed as a well-recognized discipline 
[9]. The supportive care of the    patient with any type of 
malignancy not only improves the quality of life but also 
the survival when combined with protocol based specific 
treatment. 
     PICC is very crucial to supportive care of 
hematological cancer patients undergoing stem cell 
transplantation. During the transplant process, prolonged 
and severe myelosuppression occurs post high dose 
chemotherapy due to which patient requires a lot of 
supportive measures. Blood and blood products are 
transfused regularly through the PICC line to combat 
anemia and thrombocytopenia. In case of neutropenic 
sepsis, higher antibiotics as well as anti-fungals are 
administered easily with the help of PICC. Daily blood 
counts are done until the   engraftment of neutrophils 
which might take about ten to fifteen days in average. 
Total parenteral nutrition along with electrolytes support is 
given if patient develops severe mucositis as toxicity due 
to chemotherapy. Despite of these utmost significances, 
PICCs may develop various complications of which 
catheter related blood stream infection (CRBSI) and 
thrombosis are of paramount importance [10]. The aim of 
this study was to evaluate the efficacy and safety of the use 
of PICCs in hematological cancer patients undergoing 
hematopoietic stem cell transplantation. 
MATERIAL AND METHODS 
We conducted a prospective cohort study from June 2015 
to December 2017 in stem cell transplantation unit in our 
tertiary comprehensive cancer hospital. The study was 
approved by our institutional department review board. All 
of the patients enrolled in the study provided written 
informed consent. All the hematological cancer patients 
that were admitted in transplant unit for transplantation 
were inserted PICC.  
     Under ultrasonogram guidance, 4 Fr single lumen 
triple-valved Groshong PICC (Bard Access, USA) was         
inserted with strict aseptic care by trained PICC team 
either in Minor Operation theatre or in ward. The PICC 
was inserted into any of the major vein of the upper 
extremities, more frequently in basilic vein and secured by 
stat-lock sutureless device. Chest radiograph was 
performed in all patients to verify the correct location of 
the tip (close to cavoatrial junction). PICC trained nurses 
of our unit were responsible for catheter care daily as well 
as weekly as per the protocols to reduce the complications. 
Flushing of devices was done with 10 ml of saline before 
and after each infusion (20 ml in case of infusion of blood 
products or blood sampling). The dressing over the exit 
site was changed every 48 h or more frequently if it was 
soiled. The site of insertion was examined daily for signs 
of inflammation like edema, erythema, tenderness etc. and 
recorded in a register.  
     Proforma  was made with all the parameters related to 
PICC line, patients and transplant such as name, age, sex, 
date from insertion and removal of PICC, diagnosis, 
patient status, type of vein accessed, complication (if any), 
PICC dwell days etc. Data were collected in pre-designed 
proforma, entered in MS-Excel chart and converted to 
SPSS software for final analysis. Categorical variables 
were described by frequency distribution and percentages. 
Continuous variables were expressed by means and 
standard deviations. The rates of complications were 
expressed by percentage and per 1,000 catheter days. For 
the analysis, each PICC placement was counted as a new 
event. In case of Lost to follow up patients, last visit was 
taken as the date of removal of PICC line. After the initial 
overall study of PICC in transplant cohort, the study of 
PICC was done as per the types of transplantation – 
autologous and allogenic. Finally our study result was 
compared with the other similar studies that have used 
PICC in hematological   cancer patients for transplantation. 
RESULTS 
A total of 72 PICCs were inserted successfully during the 
study period in 65 patients of which one patient had three 
PICCs inserted, five patients had two PICCS inserted and 
two PICCs were lost to follow up. The demographic 
profile of patients and PICCs details were listed in Table 1. 
Overall, the patient population included 32(49%) men and 
33(51%) women, with a mean age of 41.66 +/_ 14.67 
years (range- 7 to 67years). Age group 45-64 was the most 
common age group. Lymphoma (35%) was the most 
common of the haematological malignancies. The basilic 
vein (84.7%) was used most frequently for PICC 
placement. Weekly follow-up for these patients was 
arranged with PICC team in transplant unit or minor 
operation theatre for dressing. 
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Table 1: Characteristics of the patients receiving a 
PICC. 
 Characteristics No. of 
patients 
(n=65) (%)       
Age (years) 07 - 24                                                  6 (9.3%)
25 -44 24 (36.9%) 
45 - 64 34 (52.3%) 
65 - 84 1 (1.5%) 
Mean Age  41.6 +/_ 14.6 
Sex Male 32 (49%) 
Female 33 (51%) 
Underlying 
Cancers 
AML 15 (23.07%) 
Lymphoma 23 (35.38%) 
ALL 5 (7.7%) 
Multiple myeloma 17 (26.15%) 
Others 5 (7.7%) 
Site Of PICC 
Line 
Right basilic vein                                  14 (19.44%) 
Left basilic vein                                  47 (65.28%) 
Right cephalic vein                                  0 (0%) 
Left cephalic vein                                  6 (8.34%) 
Right brachial vein                                   3 (4.16%)
Left brachial vein                                   2 (2.78%)
  Number of 
PICCs (n=72) 
(%) 
Complications CRBSI 5 (6.9%) 
Phlebitis 2 (2.77%) 
Blockage 0 (0%) 
Accidental Removal  2 (2.77%) 
Leakage 0 (0%) 
Thrombosis 2 (2.77%) 
Abnormal position 0 (0%) 
Hematoma 0 (0%) 
Total PICCs 
removed                                            
Removal due to death                        13 (18%) 
Removal due to
complications          
11 (15.3%) 
Removal after 
completion of 
treatment without 
complications 
46 (63.9%) 
lost to follow up                                    2 (2.8%)
The 72 PICCs were in place for a total of 8048 catheter 
days (mean of 111.77 +/_ 66.55 days i.e. 3.7months and 
range, 9 to 269 days). The mean numbers of attempts on 
skin puncture during PICCS insertion were 1 attempt with 
mean duration of 26 minutes for PICCs insertion .The 
mean depth of PICCs inserted into the arms were about 
1cm and the length of PICCs was about 38cm .Of these 72 
,11 (15%) PICCs had complications and all of them were 
removed at the rate of 1.35/1000 PICC-days. Total 7 
patients out of 72 patients (9.7%) had infections with the 
incidence rate of 0.86 per thousand catheter days. Infective 
complications included 5 CRBSI and 2 phlebitis. During 
the study 5(6.9%) patients had blood culture positivity out 
of which 1 (1.38%) cases had PICC tips positivity and 1 
patient had combined positivity. Blood culture showed 
growth of staphylococcus species which was sensitive to 
common antibiotics like penicillin and cephalosporin 
groups. Total 2 out of 72 patients (2.77%) developed 
thrombosis in the PICC line which is at the rate of 0.24 per 
thousand catheter days. Patients were started with low 
molecular weight heparin till thrombosis resolved out .The 
reasons for the catheter removal were the following: 
completion of therapy (46 patients, 63 %), catheter-related 
thrombosis (2 patients, 2.77 %), Infections (7 patients, 
9.7%) accidental catheter removal (2 patients, 2.77 %), and 
death (13 patients, 18 %) due to other reasons. 
 
Table 2: Characteristics of Stem Cell Transplant. 
 
Characteristics Autologous 
Transplant 
Allogenic 
Transplant 
Number of patients  40 25 
Male 21 11 
Female 19 14 
Mean Dwell 
Time(days) 
110 145 
Most common 
malignancy 
Lymphoma AML 
CRBSI 1(2.5%) 4(16%) 
Thrombosis 0 2(8%) 
Mortality due to 
PICCs 
complications 
0 0 
 Mortality due to 
other complications 
3(7.5%) 10(40%) 
Treatment 
Completed 
37 15 
 
Out of the total 65 hematopoietic stem cell transplantation, 
40(61.5%) transplant were autologous transplant and 
25(38.5%) were allogenic transplant as depicted in Table 
2.The most common malignancy was lymphoma in 
autologous transplant group and AML in allogenic 
transplant group. CRBSI was higher in allogenic transplant 
group (16%) than in autologous group (2.5%) while all the 
thrombosis was present in allogenic group only. This 
discrepancy could be due to prolonged use of 
chemotherapy multiple blood and blood products 
transfusion and prolonged myelosuppression. Mortality 
due to PICC complications was zero in both the groups 
however      mortality due to other causes was higher in 
allogenic transplant (40%) than in the autologous group 
(7.5%). The most common cause of mortality in our study 
was infections other than CRBSI. 
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DISCUSSION 
     PICCs are now being increasingly used in 
hematopoietic stem cell transplantation  due to ease of 
insertion, low procedure related complications and less 
financial expense which also helps in cutting down of 
transplant cost [11]. In a study by Harter et al [12] they 
described the use of PICC in a cohort of 66 hematological 
patients undergoing autologous stem cell transplantation 
with an overall success rate for insertion of 94 %, a low 
incidence of complications  (phlebitis 7.6 %, CRBSI 3%). 
Hence, they concluded that PICC might be successfully 
used for high dose chemotherapy and autologous stem cell 
transplantation. However, time for PICC removal was very 
short for this series, with a median duration of 
catheterization of 8.9 days. 
In an another study by Silvia Bellesi et al [4] regarding use 
of PICCs in 57 patients undergoing autologous  stem cell 
transplantation, the incidence of CRBSI was low (3.3 %), 
despite severe neutropenia developed in all patients 
following the conditioning regimen. The incidence of 
catheter- related thrombosis was also low (5 %). They 
concluded that PICCs are a safe and effective alternative to 
conventional central venous catheters even in patients 
particularly prone to infective and hemorrhagic 
complications such as patients receiving autologous stem 
cell transplantation. 
In a study by Alessandra Malato et al [13] regarding use of 
PICCs in 72 patients undergoing both autologous and 
allogenic stem cell transplantation they had an incidence 
rate of 2.63% in both CRBSI and thrombotic        
complications with a mean dwell time of 112 days .They 
concluded that lymphoma and leukemia patients have 
respectively an increased risk of developing a CRBSI and 
a thrombotic PICCs-complication when submitted to 
haematopoietic stem cell transplantation (HSCT). 
In our study, we had a success rate of 100% PICC 
insertion by trained specialist with ultrasonogram guidance 
of strict aseptic procedure. It was relatively safe procedure 
as we didn’t have any case of local hematoma after the 
procedure and we have very less incidence with phlebitis 
(2.77%).The incidence of CRBSI was higher (6.9 %), most 
likely due to severe and prolonged myelosuppression 
especially in allogenic transplant following the 
conditioning regimen .The incidence of catheter related  
thrombosis was  very low (2.77 %), probably due to 
regular dressing and monitoring of the PICCs .The 
thrombosis rate of our study was lesser than Harter et al 
[12]  and  Silvia et al [4]  studies  however the CRBSI rate 
was almost double in our study than the other three 
studies. The use of antibiotic lock of tunneled central vein 
catheters is an effective strategy for catheter salvage in 
HSCT patients with catheter colonization and CRBSI [14].
 
However, we didn’t have data to analyze regarding use of   
antibiotic lock for CRBSI prevention in our study. 
The strength of this study lies in the fact that this is one of 
the considerable number of patients data onto PICCs used 
in a supportive care for hematopoietic stem cell 
transplantation in Indian hematological cancer patients. 
However, this analysis couldn’t reveal about comparison 
of the other central venous access methods used in stem 
cell transplantation. 
CONCLUSION 
PICC provides relatively safe and persuasive alternative 
mode of central venous access for hematopoietic stem cell 
transplantation even in Indian cancer settings. PICC forms 
an integral part of supportive care in hematopoietic stem 
cell transplantation in hematological cancers. CRBSI is of 
little concern especially in allogenic stem cell 
transplantation which needs to be addressed properly 
.However more prospective study is needed with large 
population of cohorts for further validation. 
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